Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.58 |
| ▸ | DRD1 | P21728 | 2/20 | 0.58 |
| ▸ | DRD4 | P21917 | 1/20 | 0.58 |
| ▸ | DRD5 | P21918 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 3/20 | 0.50 |
| ▸ | HTR7 | P34969 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6651356 | 0.88 | DRD2 (0.44) | DRD2DRD1DRD4DRD5HRH1 | |
| Citric Acid SCHEMBL8657218 | 0.85 | KDM4E (0.70) | DRD2DRD1DRD4DRD5HRH1 | |
| SCHEMBL6650105 | 0.83 | NR4A2 (0.42) | DRD2DRD1DRD4DRD5KDM4E | |
| SCHEMBL6651166 | 0.80 | KDM4E (0.38) | DRD2DRD1DRD4DRD5HTR7 | |
| Dimethylamine SCHEMBL7755880 | 0.80 | THRB (0.44) | HTR7LMNAALDH1A1 | |
| SCHEMBL6673116 | 0.79 | HRH1 (0.54) | DRD2DRD1DRD4DRD5HRH1 | |
| SCHEMBL5599334 | 0.79 | ADRB2 (0.35) | DRD2DRD1DRD4DRD5HRH1 | |
| SCHEMBL4303080 | 0.77 | HTR7 (0.36) | DRD2DRD1DRD4DRD5HTR7 | |
| SCHEMBL4909282 | 0.77 | KAT2B (0.34) | DRD2DRD1DRD4DRD5HTR7 | |
| SCHEMBL7755873 | 0.76 | MAOA (0.40) | DRD2DRD1DRD4DRD5HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142929-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-07-22 | — | — | US | disclosed |
| EP-0808308-B1 | METHOD FOR SEPARATING CARBINOLS | ESTEVE LABOR DR (ES) | 2001-03-07 | — | — | EP | disclosed |
| US-5849931-A | Process for separating carbinols | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 1998-12-15 | — | — | US | disclosed |
| EP-0808308-A1 | METHOD FOR SEPARATING CARBINOLS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1997-11-26 | — | — | EP | disclosed |
| WO-1997020817-A1 | METHOD FOR SEPARATING CARBINOLS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142929-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence | AADAC, AHR, ABAT | DRD2 1336/4885DRD1 1457/4885DRD4 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.